10-K: Global Innovative Platforms Inc. Files 10-K, Outlines Heartworm Breath Test Development

Global Innovative Platforms Inc. has filed its annual 10-K report, detailing its development of a breath test for heartworm detection in dogs and its financial status.

Summary

• Global Innovative Platforms Inc. is a medical technology company focused on developing a breath test to detect heartworm in dogs, aiming to replace the current adult female antigen blood test.
• The company's technology uses a VOCAM device to collect breath samples, which are then analyzed using artificial intelligence to identify specific breath prints associated with heartworm.
• The company is in the development stage, with verification and validation studies planned for the components and the heartworm breath test, with data collection expected to be completed in 2025.
• The company has identified VOCs that they believe will indicate the presence of heartworms immediately in dogs.
• The market for heartworm testing is estimated to be around 10 million dogs annually in the U.S., with each test costing between $30 and $50.
• The company has licensed a VOCAM device for use in dogs and agriculture and is working with existing labs for sample analysis.
• The company has not generated any revenue for the years ended September 30, 2023 and 2022 and has a stockholders deficit of approximately $363,953 as of September 30, 2023.
• The company's financial statements include an explanatory paragraph from their auditors stating there is substantial doubt about their ability to continue as a going concern.
• The company is dependent on outside financing to implement its business plan and has received informal funding from shareholders.
• The company has identified a material weakness in its internal controls over financial reporting due to a lack of personnel with accounting expertise and inadequate segregation of duties.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a lack of revenue, a substantial deficit, and a going concern warning from auditors. While the technology has potential, the company's current financial state and operational delays raise serious concerns for investors.

Positives

• The company's breath test technology is non-invasive and could be more convenient than current blood tests.
• The breath test has the potential to detect heartworm at all stages of its life, unlike the current antigen test which requires the heartworm to be 6 months old.
• The company's technology has potential applications beyond heartworm detection, including food safety and other diseases.
• The company has a license for the VOCAM device, which is already in production.
• The company is targeting a large market with significant potential for growth.

Negatives

• The company has not generated any revenue for the years ended September 30, 2023 and 2022.
• The company has a significant stockholders deficit of approximately $363,953.
• The company's auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• The company has a material weakness in its internal controls over financial reporting.
• The company is dependent on outside financing to implement its business plan.
• The company has a limited operating history and has made limited progress on its business plan.
• The company has experienced delays in implementing its business plan.

Risks

• The company's technology is novel and there is no guarantee of its safety and effectiveness.
• There is a risk of incorrect results from the breath test, such as false negatives, which could lead to delayed treatment.
• The company may not be able to meet its development milestones or achieve market acceptance.
• The company is dependent on outside financing and may not be able to obtain it on acceptable terms.
• The company faces competition from established venture capital and financial concerns with greater resources.
• The company's principal shareholders control a significant portion of the stock and may act in their own best interests.
• The company is an emerging growth company and may take advantage of reduced disclosure requirements, which could make its stock less attractive to investors.
• The company's stock is thinly traded and investors may not be able to sell their shares at a desirable price.
• The company's business plan is expected to result in dilution of existing shareholders' ownership.
• The company's securities are subject to penny stock regulations, which may affect their tradability.

Future Outlook

The company plans to complete verification and validation studies for its heartworm breath test components and the test itself in 2025, with data collection to be completed shortly thereafter. The company anticipates the completion of the components, the Heartworm Breath Test, and the verification and validation studies in 2025 that will be acceptable to begin commercialization. The company also intends to pursue other applications of its breath analytics platform.

Management Comments

• The company believes that the Heartworm Breath Test may be of substantial importance in preventing impairment of health through the diagnosis of a life-threatening disease for dogs.
• The company believes that the Heartworm Breath Test will bring forth a novel and differentiated tool that will assist veterinarians in making decisions about treatment.
• The company believes that breath analytics is an accessible, non-invasive, and convenient method for detecting disease.
• The company is confident that its artificial intelligence software will be reliable for its purposes.
• The company considers obtaining Mindspace to be the most sensitive to its overall success.

Industry Context

The company is entering the veterinary diagnostics market, which is experiencing growth due to advancements in technology and increased pet ownership. The company's focus on breath analysis is a novel approach compared to traditional blood tests, and if successful, could disrupt the market. The company is targeting the heartworm testing market, which is a significant segment of the veterinary diagnostics industry.

Comparison to Industry Standards

• The current standard for heartworm testing is the adult female antigen blood test, which requires the heartworm to be at least 6 months old to be detected. Global Innovative Platforms' breath test aims to detect heartworm at all stages of its life, which would be a significant improvement.
• The company's technology is based on breath analysis, which is a non-invasive method, unlike blood tests. This could make testing more convenient and less stressful for animals.
• The company is using artificial intelligence to analyze breath samples, which is a growing trend in medical diagnostics. This could lead to more accurate and efficient testing.
• The company is competing with established veterinary diagnostic companies such as IDEXX Laboratories and Zoetis, which have significantly greater financial and personnel resources. The company's success will depend on its ability to differentiate its technology and gain market acceptance.
• The company's financial situation is significantly weaker than industry leaders, with no revenue and a substantial deficit. This will make it challenging to compete and scale its operations.

Management Changes

Corporate Governance

Legal Proceedings

• Neither the company nor any of its officers, directors, or holders of five percent or more of its common stock is a party to any pending legal proceedings.

Related Party Transactions

• Three shareholders advanced the company $50,000, $50,000, and $1,115 for the year ended September 30, 2022 and an additional $50,000, $125,000, and $10,903 for the year ending September 30, 2023.
• The company's executive office is furnished by its CEO at no charge.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution.
• Employees are limited, with no full-time staff and part-time contractors.
• Customers (veterinarians and pet owners) could benefit from the company's technology if it is successfully developed and commercialized.
• Suppliers and creditors face risk due to the company's financial instability.
• The company's technology could potentially improve the health and well-being of animals.

Next Steps

• The company plans to complete verification and validation studies for its heartworm breath test components and the test itself in 2025.
• The company plans to complete data collection for the heartworm breath test in 2025.
• The company plans to analyze the data collected from the heartworm breath test.
• The company plans to complete the components, the Heartworm Breath Test, and the verification and validation studies in 2025 that will be acceptable to begin commercialization.
• The company intends to pursue other applications of its breath analytics platform.

Key Dates

Keywords

heartworm, breath test, veterinary, medical technology, VOCAM, artificial intelligence, diagnostics, animal health, biomarkers, volatile organic compounds